Contact Cystic fibrosis programs CF is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide and approximately 30,000 patients in the United States. CF is a chronic disease that affects the lungs and digestive system. CF patients, with significantly impaired quality of life, have an average lifespan approximately 50% shorter than the population average, with the median age of death at 40. There currently is no cure for CF. CF patients require lifelong treatment with multiple daily medications, frequent hospitalizations and ultimately lung transplant, which is life-extending but not curative. CF is caused by a mutation in the gene for the CFTR protein, which results in abnormal transport of chloride across cell membranes. Transport of chloride is required for effective hydration of epithelial surfaces in many organs of the body. Normal CFTR channel moves chloride ions to outside of the cell. Mutant CFTR channel does not move chloride ions, causing sticky mucous to build up on the outside of the cell. CFTR dysfunction results in dehydration of dependent epithelial surfaces, leading to damage of the affected tissues and subsequent disease, such as lung disease, malabsorption in the intestinal tract and pancreatic insufficiency. Galapagos and AbbVie entered into a global alliance to discover, develop and commercialize novel therapies in cystic fibrosis (CF) in September 2013. Galapagos and AbbVie aim to develop a triple CFTR combination therapy to address 90% of patients with CF. In order to bring a more effective therapy to patients, the companies have developed multiple candidates and backups for each of the three components of a potential triple combination. Triple combinations of CF compounds in the portfolio have consistently shown restoration of healthy activity levels in in vitro assays with human bronchial epithelial (HBE) cells of patients with the F508del mutation. These combinations result in a statistically significant increase in chloride transport over Orkambi[1] in HBE cells with the homozygous F508del mutation. It is expected that a triple combination therapy patient study will start in 2017. [1] Orkambi® is a prescription medicine sold by Vertex Pharmaceuticals, used for the treatment of cystic fibrosis (CF) in patients age 12 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. Related publications Pharmacokinetics and safety of a novel CFTR corrector molecule GLPG2222 in Subjects with Cystic Fibrosis (CF): results from a phase Ib study ECFS, Junue 2017 GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1) ECFS, June 2017 Discovery of ABBV/GLPG-2222, a potent CFTR corrector for the treatment of Cystic Fibrosis ACS Meeting, April 2017 Discovery of Highly Efficacious Potentiators for the Treatment of Cystic Fibrosis ACS Meeting, April 2017 SAPHIRA 1 topline results webcast NACFC 2016 On track to a triple combo therapy Slide deck investor get-together, 27 October at the Rozen Plaza, Orlando Characterization of a novel potentiator series for treating Cystic Fibrosis Safety, Tolerability and Pharmacokinetics of a novel CFTR corrector molecule GLPG2222 in healthy volunteers The C.1766+1G a splice site mutation causes exon 13 skipping resulting in multiple defects in CFTR structure and function Measuring potentiator activity using organoids Characterization of novel potentiators Novel Correctors and Potentiators Augment Efficacy of Translational Readthrough in CFTR Nonsense Mutations GLPG1837 in subjects with cystic fibrosis and the S1251N mutation: results from a Phase 2a study (SAPHIRA2) Other publications Dr Katja Conrath on Galapagos' CF program at UK CF Conference Nottingham, 8 September 2016 Novel Potentiators Augment Efficacy of Translational Readthrough in CFTR Nonsense Mutations NACFC 2015 Safety, tolerability and pharmacokinetics of a novel CFTR Potentiator GLPG1837 in healthy volunteers NACFC 2015 Using BLISS analysis to categorize corrector-corrector interactions NACFC 2015 Insight into the mechanisms of correctors and potentiators NACFC 2015 Potentiators: how do they impact the fate of CFTR during biogenesis? NACFC 2015 Screening for corrector - potentiator combinations Corina Balut, et al ECFC 2015 The way forward in drug testing is mutation specific Katja Conrath ECFC 2014 Novel corrector-potentiator combinations for treating Cystic Fibrosis Katja Conrath, et al NACFC 2014 Presentation at Wells Fargo CF Seminar 2014 Piet Wigerinck Novel potentiators for treating Cystic Fibrosis Katja Conrath, et al NACFC 2013 © Copyright 2017 Galapagos NV ● Disclaimer ● Terms ● News via mail